A Study of Quality of Life and Body Image in Schizophrenia Patients with Metabolic Syndrome.
- Author:
In Seon YUN
1
;
Hyo Seon GO
;
Sang Yeol LEE
Author Information
1. Department of Psychiatry, Wonkwang University School of Medicine, Iksan, Korea. sangyeol@wonkwang.ac.kr
- Publication Type:Original Article
- Keywords:
Schizophrenia;
Metabolic syndrome;
Quality of life;
Body image
- MeSH:
Body Image;
Cholesterol;
Diagnostic and Statistical Manual of Mental Disorders;
Humans;
Prevalence;
Quality of Life;
Schizophrenia
- From:Korean Journal of Psychopharmacology
2011;22(4):208-213
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study aimed to investigate the prevalence of metabolic syndrome, associated factors in schizophrenia patients and whether metabolic syndrome have an effect on health related quality of life (QoL) and body image. METHODS: 81 subjects were included in this study, who were diagnosed as schizophrenia defined by DSM-IV criteria and admitted in neuropsychiatric department, Wonkwang University Hospital. For each subject, anthropometric index and laboratory parameters were measured. Metabolic syndrome defined by National Cholesterol Education Program-Adult Treatment Panel III. The subjects were evaluated health related QoL with Short-Form 36 Health Survey-Korean (SF-36-K), and were evaluated body image with Body Image Scale. RESULTS: Of patients, 24.7% had metabolic syndrome. Metabolic syndrome was associated with long duration of illness. The patients with metabolic syndrome showed poorer QoL, especially role physical and bodily pain in SF-36-K. Also, the patients with metabolic syndrome had negative body image, especially body feature, compared to the patients without metabolic syndrome. CONCLUSION: This study suggests that metabolic syndrome is common among patients with chronic schizophrenia. Also It may lead to lowering of QoL and deterioration of body image. So clinicians should be cautious to aware the increased risk for the metabolic syndrome and intervene actively to prevent and treat metabolic morbidity among chronic patients with schizophrenia.
